Showing 81-90 of 115 results for "".
What Will Be Our Legacy?
https://practicaldermatology.com/topics/practice-management/what-will-be-our-legacy/21434/Practical Dermatology® Magazine Welcomes Neal Bhatia, MD, FAAD as Co-Chief Medical EditorMentors in Dermatology
https://practicaldermatology.com/topics/practice-management/mentors-in-dermatology/18719/Neal Bhatia, MD sat down with one of his mentees, Al Damavandy, MD, to discuss what makes a great mentee-mentor relationship and how both parties can benefit. Dr. Damavandy, now a practicing Mohs Surgeon and Dermatologist, shared tips for how to find the right mentor and what he learned from his menThe Rising Costs of Prescription Drugs
https://practicaldermatology.com/topics/practice-management/the-rising-costs-or-prescription-drugs/18677/What's really causing the costs of dermatology prescriptions, especially generics, to skyrocket? Jake Levitt, MD and Mark Lebwohl, MD speak to host Neal Bhatia, MD about what's influencing these rising costs, and who, if anyone, is benefiting. Dr. Levitt talks about the rebate system between manufacMy Lumixyl Experience
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/my-lumixyl-experience/19444/A patient of Dr. Ashish Bhatia's, describes her experience using Lumixyl Brightening System for her adult acne.- Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluzhttps://practicaldermatology.com/news/biofrontera-inc-announces-fda-filing-of-supplemental-new-drug-application-for-ameluz/2462237/Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has issued a "no filing review issues identified" letter regarding the sNDA (supplementary New Drug Application) submitted b…
- Roflumilast Formulations Show Favorable Tolerability Across Several Trials: Analysishttps://practicaldermatology.com/news/roflumilast-formulations-show-favorable-tolerability-across-several-trials-analysis/2462229/Investigator- and patient-rated assessments indicated that topical roflumilast was tolerable and did not cause discomfort, according to a new analysis of data from several clinical trials. “Formulating a topical medication that does not irritate the skin is an important factor contributing to pati…
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. In what has become a popular annual tradition at Maui Derm, Practical Dermatology® Chief Medical Ed…
- Experts React to FDA Approval of Cabtreo Topical Gel for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-cabtreo-topical-gel-for-acne-vulgaris/2462087/The U.S. Food and Drug Administration (FDA) has approved CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel for the topical treatment of acne vulgaris in patients aged 12 and older. Bausch Health and Ortho Dermatologics' CABTREO is the first and only FDA-approved fixed-d…
- Meet Secret DUO from Cuterahttps://practicaldermatology.com/news/meet-secret-duo-from-cetera/2461986/Cutera, Inc. is launching Secret DUO, a skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications. Secret DUO is equipped with a radio frequency mi…
- Practical Dermatology® Unveils New Cover Redesign for July 2023 Issuehttps://practicaldermatology.com/news/practical-dermatology-unveils-new-cover-redesign-for-july-2023-issue/2461895/Bryn Mawr Communications, publisher of Practical Dermatology®, has announced a captivating new cover redesign for the magazine, which will debut with their upcoming July issue. This visual update signals the first of many changes coming to the publication. "We are thrilled to unveil our striking ne…